Ennaid Therapeutics | Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program
19550
post-template-default,single,single-post,postid-19550,single-format-standard,ajax_fade,page_not_loaded,,qode-theme-ver-7.7,wpb-js-composer js-comp-ver-6.2.0,vc_non_responsive

Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program

13 May Catalent Signs Development Agreement with Ennaid Therapeutics on its COVID-19 Lead Program

SOMERSET, N.J. (PRWEB) MAY 13, 2020

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a collaboration with Ennaid Therapeutics to develop an oral, antiviral treatment targeted at COVID-19. Under the terms of the agreement, Catalent will develop a powder-in-capsule formulation of Ennaid’s ENU200 program, a patent-pending, repurposed oral antiviral drug.

ENU200 was selected by Ennaid as a candidate to treat COVID-19 following a bioinformatic search for in silico identification of prior-approved chemical compounds blocking the coronavirus proteins, spike-S glycoprotein and the key coronavirus enzyme, Mpro. Catalent’s development site at San Diego will manufacture roller-compacted formulations of ENU200 within capsules for further investigation.

Read the rest of the article on CISION’s site HERE

No Comments

Post A Comment